Sensei Says First Patient Dosed In Phase 1/2 Clinical Trial Of SNS-101, A Conditionally Active VISTA-blocking Antibody, For Treatment Of Advanced Solid Tumors
Portfolio Pulse from Benzinga Newsdesk
Sensei Biotherapeutics announced the first patient dosed in a Phase 1/2 clinical trial of SNS-101, a conditionally active VISTA-blocking antibody, for the treatment of advanced solid tumors. SNS-101 is designed to selectively block the immune checkpoint VISTA in the tumor microenvironment.
June 01, 2023 | 11:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sensei Biotherapeutics has dosed the first patient in a Phase 1/2 clinical trial of SNS-101, a VISTA-blocking antibody for advanced solid tumors treatment.
The initiation of the Phase 1/2 clinical trial for SNS-101 is a significant milestone for Sensei Biotherapeutics. Positive results from the trial could lead to increased investor confidence and potential stock price appreciation in the short term. The news is highly relevant and important for investors in SNSE, as it directly pertains to the company's product pipeline and potential future revenues.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100